A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Inclusion Criteria: * 1\. Histopathologically confirmed renal clear cell cancer, including advanced renal cell carcinoma with clear cell components. 2\. Has not receiving systemic therapy for local advanced/metastatic disease. 3. At least has one measurable lesion. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Life expectancy ≥ 3 months. 5\. Adequate laboratory indicators. 6. Agree to provide at least 5 slices tumor tissue samples for biomarker detection. 7\. Serum or urine pregnancy tests are negative within 7 days before randomization; Men and women should agree to use effective contraception during the study period and after the end of the study period within 6 months. 8\. Understood and signed an informed consent form. Exclusion Criteria: * 1\. Has symptomatic central nervous system (CNS) disease and / or cancerous meningitis, pia mater disease. 2\. Has received anti-angiogenesis targeted therapy or targeted PD-1 and PD-L1 immunotherapy. 3\. Has active virus, bacteria, fungal infection; Cardiovascular and cerebrovascular diseases; Gastrointestinal abnormalities; Immunodeficiency; Bleeding risk; Lung disease; Neurological or psychiatric disorders. 4\. Has participated in other clinical trials within 30 days before randomization. 5\. Has received attenuated live vaccine within 28 days before randomization or planned to received attenuated live vaccine during the study period. 6\. Pregnant or lactating women. 7. According to the judgement of the investigators, there are other factors that may lead to the termination of the study.